Trial Profile
A prospective, observational study of Nilotinib as second-line treatment to Imatinib in a real life setting chronic myeloid leukaemia in chronic phase
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 05 Mar 2018 New trial record
- 01 Feb 2018 French nationwide large cohort efficiency and safety results (n=150) of Nilotinib in the treatment of patients with CP-CML were published in the British Journal of Haematology